Literature DB >> 21730780

Primary colectomy in patients with stage IV colon cancer and unresectable distant metastases improves overall survival: results of a multicentric study.

Mehdi Karoui1, Françoise Roudot-Thoraval, Farida Mesli, Emmanuel Mitry, Thomas Aparicio, Gaetan Des Guetz, Gaetan DesGuetz, Christophe Louvet, Bruno Landi, Emmanuel Tiret, Iradj Sobhani.   

Abstract

BACKGROUND: Whether patients with stage IV colon cancer and unresectable distant metastases should be managed by primary colectomy followed by chemotherapy or immediate chemotherapy without resection of the primary tumor is still controversial.
OBJECTIVE: This study aimed to evaluate predictive factors associated with survival in patients with stage IV colon cancer and unresectable distant metastases.
DESIGN: This large retrospective multicentric study included 6 academic hospitals. SETTINGS: This study was conducted at 6 Paris University Hospitals (Assistance Publique-Hôpitaux de Paris; Saint Antoine, Henri Mondor, Ambroise Paré, Hôpital Europeen Gorges Pompidou, Bichat, and Avicenne). PATIENTS: Between 1998 and 2007, 208 patients with good performance status and stage IV colon cancer with unresectable distant metastases received chemotherapy, either as initial management or after primary tumor resection. MAIN OUTCOME MEASURES: Survival was estimated by use of the Kaplan-Meier method. Factors associated with survival were tested by means of a log-rank test. Results were expressed as median values with 95% confidence intervals. Factors independently related to survival were tested using a Cox regression model adjusted for a propensity score.
RESULTS: Of the 208 patients, 85 underwent colectomy before chemotherapy, whereas 123 were treated with use of primary chemotherapy with or without biotherapy. At univariate analysis, the following factors were significantly associated with survival: primary colectomy (P = .031), secondary curative surgery (P < .001), well-differentiated primary tumor (P < .001), exclusive liver metastases (P < .027), absence of need for colonic stent (P = .009), and addition of antiangiogenic (P = .001) or anti-epidermal growth factor receptor (P = .013) drugs to chemotherapy. After Cox multivariate analysis and after adjusting for the propensity score, all of these factors, with the exception of two, colonic stent and anti-epidermal growth factor receptor drug, were found to be independently associated with overall survival. LIMITATION: This study was limited by its retrospective nature.
CONCLUSIONS: In a selected population of patients with colon cancer and unresectable synchronous distant metastases, immediate colectomy followed by chemotherapy in association with targeted therapy was associated with longer overall survival. This strategy appears to be the most appropriate, especially for those with good performance status, well-differentiated tumors, and synchronous liver metastases only.

Entities:  

Mesh:

Year:  2011        PMID: 21730780     DOI: 10.1097/DCR.0b013e31821cced0

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  33 in total

Review 1.  Advances in the management of colorectal cancer: from biology to treatment.

Authors:  Shahid Ahmed; Kate Johnson; Osama Ahmed; Nayyer Iqbal
Journal:  Int J Colorectal Dis       Date:  2014-06-24       Impact factor: 2.571

2.  Prognostic value of angiopoietin-2 for death risk stratification in patients with metastatic colorectal carcinoma.

Authors:  Marine Jary; Dewi Vernerey; Thierry Lecomte; Erion Dobi; François Ghiringhelli; Franck Monnien; Yann Godet; Stefano Kim; Olivier Bouché; Serge Fratte; Anthony Gonçalves; Julie Leger; Lise Queiroz; Olivier Adotevi; Franck Bonnetain; Christophe Borg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-01-12       Impact factor: 4.254

3.  Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4).

Authors:  Sebastiano Biondo; Ricardo Frago; Esther Kreisler; Eloy Espin-Basany
Journal:  Int J Colorectal Dis       Date:  2017-05-11       Impact factor: 2.571

4.  Treatment strategy for colorectal cancer with resectable synchronous liver metastases: Is any evidence-based strategy possible?

Authors:  Luca Viganò
Journal:  World J Hepatol       Date:  2012-08-27

Review 5.  Should noncurative resection of the primary tumour be performed in patients with stage iv colorectal cancer? A systematic review and meta-analysis.

Authors:  S Ahmed; R K Shahid; A Leis; K Haider; S Kanthan; B Reeder; P Pahwa
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

6.  Analysis of surgical complications of primary tumor resection after neoadjuvant treatment in stage IV colon cancer.

Authors:  Jorge Arredondo; Patricia Martínez; Jorge Baixauli; Carlos Pastor; Javier Rodríguez; Fernando Pardo; Fernando Rotellar; Ana Chopitea; José Luís Hernández-Lizoáin
Journal:  J Gastrointest Oncol       Date:  2014-04

Review 7.  VEGF levels and the angiogenic potential of the microenvironment can affect surgical strategy for colorectal liver metastasis.

Authors:  Clarisse Eveno; Marc Pocard
Journal:  Cell Adh Migr       Date:  2012-11-01       Impact factor: 3.405

Review 8.  Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review.

Authors:  Louis de Mestier; Gilles Manceau; Cindy Neuzillet; Jean Baptiste Bachet; Jean Philippe Spano; Reza Kianmanesh; Jean Christophe Vaillant; Olivier Bouché; Laurent Hannoun; Mehdi Karoui
Journal:  World J Gastrointest Oncol       Date:  2014-06-15

Review 9.  [Metastasized colonic cancer. When are there no indications for primary resection?].

Authors:  R Kube; P Mroczkowski
Journal:  Chirurg       Date:  2015-02       Impact factor: 0.955

10.  The Role of Surgery for Asymptomatic Primary Tumors in Unresectable Stage IV Colorectal Cancer.

Authors:  Young Wan Kim; Ik Yong Kim
Journal:  Ann Coloproctol       Date:  2013-04-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.